Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
PYC Therapeutics Limited ( (AU:PYC) ) has issued an announcement.
PYC Therapeutics has applied for quotation on the ASX of 31,197,631 new fully paid ordinary shares, with an issue date of March 6, 2026. The securities arise from previously announced transactions and their quotation will expand the company’s listed share base, potentially increasing liquidity and broadening its investor participation.
The move to quote these additional shares reflects ongoing capital-related activity that may support PYC Therapeutics’ funding capacity for its therapeutic development programs. The enlarged pool of tradable securities could influence market dynamics around the stock, including trading volumes and ownership structure among existing and new shareholders.
The most recent analyst rating on (AU:PYC) stock is a Hold with a A$1.50 price target. To see the full list of analyst forecasts on PYC Therapeutics Limited stock, see the AU:PYC Stock Forecast page.
More about PYC Therapeutics Limited
PYC Therapeutics Limited is a biotechnology company listed on the ASX under the code PYC. The company operates in the therapeutics sector, focusing on the development of medical treatments and related technologies for healthcare markets.
Average Trading Volume: 923,189
Technical Sentiment Signal: Strong Buy
Current Market Cap: A$1.4B
See more data about PYC stock on TipRanks’ Stock Analysis page.